All stock lists
Spyre Therapeutics, Inc. (SYRE)
NASDAQ: SYRE · Real-Time Price · USD
Healthcare · Biotechnology
91.87+1.54 (+1.70%)
Insider Score
––Not scored
SYRE Insider Score
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
SYRE Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 |
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Growth (YoY) | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| SG&A Expense | 16.14 M | 15.23 M | 12.53 M | 11.64 M | 11.79 M |
| R&D Expense | 65.50 M | 60.41 M | 44.64 M | 45.25 M | 40.15 M |
| Operating Expenses | 81.64 M | 75.64 M | 57.17 M | 56.89 M | 51.94 M |
| Operating Income | -81.64 M | -75.64 M | -57.17 M | -56.89 M | -51.94 M |
| Pretax Income | -36.20 M | -69.00 M | -62.53 M | -11.18 M | -36.72 M |
| Tax Provision | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -36.20 M | -69.00 M | -62.53 M | -11.18 M | -36.72 M |
| EPS (Basic) | -0.43 | -0.74 | -0.70 | -0.18 | -0.60 |
| EPS (Diluted) | -0.43 | -0.74 | -0.70 | -0.18 | -0.60 |
| Shares Outstanding | 85.09 M | 78.55 M | 75.09 M | 60.78 M | 60.70 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.